

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022

<https://marketpublishers.com/r/A51F7166014EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A51F7166014EN

Abstracts

This report can be delivered to the clients within 2-3 working days

DelveInsight's, "Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Understanding

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Overview

?-syn is an abundant 14 kDa protein consisting of 140 amino acids and comprised of three domains: an N-terminal lipid-binding alpha-helix; a non-amyloid-component (NAC); and an acidic C-terminal tail. The N-terminal domain of ?-syn is characterized by a series of seven 11-residue imperfect repeats, each based upon a highly conserved KTKEGV hexameric motif that is also observed in the ?-helical domain of apolipoproteins. Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients.

Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation have been widely linked to neurotoxic pathways that ultimately lead to neurodegeneration. Such pathways include autophagy/lysosomal dysregulation, synaptic dysfunction, mitochondrial disruption, and endoplasmic reticulum (ER) and oxidative stress. Alpha-synuclein has not only been shown to alter cellular pathways but also to spread between cells, causing aggregation in host cells. Therapeutic approaches will need to address several, if not all, of these angles of alpha-synuclein toxicity.

'Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 R&D. The therapies under development are focused on novel approaches to treat/improve Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Emerging Drugs Chapters

This segment of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand

clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Emerging Drugs

UCB0599: UCB Biopharma

UCB0599 is an investigational small molecule that prevents the pathological misfolding and accumulation of alpha-synuclein, a protein which plays a role in Parkinson's disease (PD) pathology. Inhibition of alpha-synuclein misfolding has the potential to slow down the progression of PD. UCB0599 belongs to a series of molecules discovered by Neuropore, which was in-licensed by UCB in 2014. It is currently in Phase II stage of development.

Prasinezumab: Prothena Corporation/Roche

Prasinezumab is a first-in-class therapeutic with the goal of reducing clinical decline in Parkinson's disease. Prasinezumab targets β -synuclein and is designed to block the cell-to-cell transmission of the aggregated pathogenic forms of β -synuclein that are the cause of Parkinson's disease, thereby slowing clinical decline. Prasinezumab is currently in Phase IIb PADOVA study and ongoing long term extension of Phase II PASADENA study. Both studies are being conducted by the partner, Roche.

Further product details are provided in the report.....

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment

This segment of the report provides insights about the different Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021

There are approx. 13+ key companies which are developing the therapies for Alpha-

Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021. The companies which have their Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drug candidates in the most advanced stage, i.e. Phase II include, UCB Biopharma.

Phases

DelveInsight's report covers around 13+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Report Insights

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Report
Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs?

How many Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

UCB Biopharma

Lundbeck A/S

Enterin

Ionis Pharmaceuticals

Abbvie

Denali Therapeutics

Key Products

UCB0599

Lu AF82422

ENT-01

ION-464

ABBV-0805

ATV:~Syn

Contents

Introduction

Executive Summary

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

UCB0599: UCB Biopharma

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early stage products (Phase I)

- Comparative Analysis

Lu AF82422: Lundbeck A/S

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Preclinical stage products

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Key Companies

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Key Products

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021- Unmet Needs

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021- Market Drivers
and Barriers

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/A51F7166014EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A51F7166014EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970